Category: Fatty Liver

All Podcast Categories
S4-40.4 - Challenges in Treating and Assessing Adequately

S4-40.4 – Challenges in Treating and Assessing Adequately

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a conversation around the complex challenges in adequately assessing and treating patients.

S4-40.3 - Which test is best for which patients?

S4-40.3 – Which test is best for which patients?

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. In this conversation, presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green to ask and answer questions surrounding the task of testing patients for optimized results under different scenarios.

S4-40.2 - Deeper Dive into the Landscape of NITs

S4-40.2 – Deeper Dive into the Landscape of NITs

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.

S4-40.1 - Liver as a Regenerative Organ and the Use and Limitations of NITs

S4-40.1 – Liver as a Regenerative Organ and the Use and Limitations of NITs

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.

S4-40 - Review of Paris NASH 2023

S4-40 – Review of Paris NASH 2023

Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for an exciting episode that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. Surf on to learn much more from what always pans out to be an incredibly in-depth and insightful event.

S4-39.4 - MASEF: Where will we be in 2 years?

S4-39.4 – MASEF: Where will we be in 2 years?

Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This final session considers a few more populations who might benefit from such a test before the panelists field a final question that speculates what MASEF will look like 2 years from today.

S4-39.3 - MASEF: Next Steps and New Cohorts

S4-39.3 – MASEF: Next Steps and New Cohorts

Mazen Noureddin discusses his work on a Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF) with Jörn Schattenberg, Louise Campbell and Roger Green. This conversation considers applying the test to pediatric populations and the newly classified Met-ALD population (those with MASLD who consume greater amounts of alcohol per week). Additionally, the group considers what’s next for MESAF and how metabolomic tests are becoming commercially available in different countries.

S4-39.1 - MASEF: Study Parameters and Notable Results

S4-39.1 – MASEF: Study Parameters and Notable Results

In this conversation, Mazen Noureddin introduces his recent work around serum identification of at-risk MASH and the recent paper he co-authored on the subject. He describes the aims of the study as well as provides a cogent background for why this work came to be and maintains its relevance.

S4-39 - The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

S4-39 – The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

Surfing NASH returns to its regular program with a fresh episode and some fascinating and progressive ideas on non-invasive testing with Mazen Noureddin. For this feature, Mazen talks about his recent work in serum identification of at-risk MASH and the Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF). The Surfers (Jörn Schattenberg, Louise Campbell and Roger Green) respond with their thoughts and varying perspectives.

S4-38.4 - On the Capabilities of The Health Care Systems

S4-38.4 – On the Capabilities of The Health Care Systems

Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.